# Biospectal

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biospectal

- Industry: Healthcare IT
- Headquarters: Lausanne, Switzerland
- Website: www.biospectal.com
- Total disclosed funding: $4.3M
- Latest round: Seed (Jul 1, 2021)
- Investors on record: 4

## About

Founded in 2017 and based in Laussane, Switzerland, Biospectal SA develops OptiBP™ Test Program, a smartphone app and data platform that also uses a medical-grade device integrated directly into its user's smartphone for blood pressure measurement and monitoring. The company was founded by its CEO Eliott Jones, alongside Patrick Schoettker and Reinhard Stary. In July 2021, the company received its latest Seed funding from a group of investors that includes SeedLink, LabCorp, and Athensmed.

The company's product is OptiBP™, a smartphone and data platform that comes along with a medical-grade device integrated directly into its user's smartphone for blood pressure measurement and monitoring. It transforms the smartphone's camera into a medical-grade blood pressure monitoring solution allowing users to analyze and asses their condition anytime and anywhere.

The company plans to scale its OptiBP™ smartphone blood pressure monitoring application and data platform technology in the global market.

## Funding rounds

- Seed, Jul 1, 2021, $4.3M — Laboratory Corporation of America Holdings, Athensmed Oy, Privilege Ventures, SeedLink SL

## Investors

- Laboratory Corporation of America Holdings — Seed
- Athensmed Oy — Seed
- Privilege Ventures (https://capitalatlas.ai/funds/privilege-ventures) — Seed
- SeedLink SL (https://capitalatlas.ai/funds/seedlink-sl) — Seed